LC28 0126

Drug Profile

LC28 0126

Alternative Names: LC-280126; NecroX-7

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator LG Life Sciences
  • Class Cardiovascular therapies; Hepatoprotectants
  • Mechanism of Action NF-kappa B inhibitors; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatic fibrosis

Highest Development Phases

  • Phase II Myocardial infarction
  • Preclinical Pulmonary fibrosis
  • No development reported Hepatic fibrosis

Most Recent Events

  • 03 Sep 2016 Preclinical trials in Pulmonary fibrosis in South Korea (unspecified route)
  • 03 Sep 2016 Pharmacodynamics data from a preclinical study in Pulmonary fibrosis presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatic-fibrosis in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top